Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 674 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Edema Clear all
Recruiting No phase listed Observational

OCT in Fuchs' Dystrophy

NCT04258787
View directory record Official record
Conditions
Fuchs Dystrophy, Pseudophakic Bullous Keratopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

NCT01571232
View directory record Official record
Conditions
Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Interventions
dexamethasone intravitreal implant, intravitreal bevacizumab
Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

NCT00789477
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Laser Photocoagulation, Intravitreal Aflibercept Injection
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
42
States / cities
Artesia, California • Beverly Hills, California • Mountain View, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

NCT03071055
View directory record Official record
Conditions
Exudative Age Related Macular Degeneration
Interventions
Ranibizumab Injection [Lucentis]
Drug
Lead sponsor
Southeast Clinical Research Associates, LLC
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Charlotte, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema

NCT00320814
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
VEGF Trap-Eye
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

NCT03526549
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
CCH-aaes, Observation
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
42
States / cities
Glendale, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03739593
View directory record Official record
Conditions
Macular Edema
Interventions
AR-1105-CF1, AR-1105-CF2
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 28, 2026, 5:58 AM EDT
Terminated Not applicable Interventional Results available

Clinical Efficacy of Bevacizumab Combined With Navigated Laser in Patients With Clinically Significant Macula Edema

NCT02032238
View directory record Official record
Conditions
Clinically Significant Macular Edema
Interventions
laser photocoagulation
Device
Lead sponsor
OD-OS GmbH
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 28, 2026, 5:58 AM EDT
Not listed Not applicable Interventional

BFR DISTRAD NON OP: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture

NCT03056950
View directory record Official record
Conditions
Distal Radius Fracture, Rehabilitation
Interventions
DELFI PTS ii portable tourniquet
Device
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 28, 2026, 5:58 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Study Evaluating Retinal Health Monitoring System Thickness Module

NCT04428242
View directory record Official record
Conditions
Macular Edema, Macular Degeneration
Interventions
RHMS-RTM, SD-OCT
Device · Diagnostic Test
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients

NCT01948388
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
corticotrophin 80 units
Drug
Lead sponsor
Gaylis, Norman B., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 28, 2026, 5:58 AM EDT
Active, not recruiting Phase 4 Interventional

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

NCT07118670
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Aflibercept 8mg
Drug
Lead sponsor
Edward Wood, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Austin, Texas • Bellaire, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 28, 2026, 5:58 AM EDT
Completed No phase listed Observational

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

NCT02188173
View directory record Official record
Conditions
Macular Edema
Interventions
dexamethasone 700 ㎍ intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Santa Ana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 28, 2026, 5:58 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)

NCT06942520
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
Genetic · Biological
Lead sponsor
Sierra Eye Associates
Other
Eligibility
25 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

NCT01277302
View directory record Official record
Conditions
Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Subchondroplasty® Knee RCT

NCT03112200
View directory record Official record
Conditions
Bone Marrow Edema, Knee Pain Chronic, Knee Osteoarthritis, Osteoarthritis, Knee, Osteoarthritis
Interventions
Subchondroplasty with Arthroscopy, Arthroscopy Alone
Procedure
Lead sponsor
Zimmer Biomet
Industry
Eligibility
30 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
Encinitas, California • Loma Linda, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 28, 2026, 5:58 AM EDT
Terminated Not applicable Interventional Results available

Uterine Filling Pressure in Hysteroscopy

NCT04550429
View directory record Official record
Conditions
Fibroids
Interventions
MyoSure Hysteroscopic Morcellator Device
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

NCT02186119
View directory record Official record
Conditions
Macular Edema
Interventions
abicipar pegol, ranibizumab, sham procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
19 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Gilbert, Arizona • Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 4 Interventional

Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.

NCT01244334
View directory record Official record
Conditions
Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration, Visual Acuity Reduced Transiently
Interventions
Difluprednate ophthalmic emulsion 0.05%, Prednisolone acetate 1%
Drug
Lead sponsor
Edward J. Holland
Other
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Edgewood, Kentucky • Lynbrook, New York • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

NCT00090519
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
ruboxistaurin, placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
36
States / cities
Artesia, California • Palm Springs, California • Poway, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antibiotic Efficacy in Third Molar Surgery

NCT00118820
View directory record Official record
Conditions
Alveolar Osteitis, Dry Socket, Infection
Interventions
IV Preoperative antibiotic or placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2010 · Synced Oct 28, 2026, 5:58 AM EDT
Completed No phase listed Observational

Diabetic Retinopathy and Visual Function Study

NCT00001346
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Vision, Subnormal
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO

NCT02387788
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
AKB-9778
Drug
Lead sponsor
Aerpio Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 28, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema

NCT06181227
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
AVD-104
Drug
Lead sponsor
Aviceda Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Erie, Pennsylvania • Dallas, Texas • Wichita Falls, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 28, 2026, 5:58 AM EDT